

Julia Dietz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/952411/publications.pdf>

Version: 2024-02-01

24
papers

580
citations

759055

12
h-index

610775

24
g-index

24
all docs

24
docs citations

24
times ranked

1183
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	0.6	132
2	Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>Journal of Virology</i> , 2013, 87, 6172-6181.	1.5	88
3	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0134395.	1.1	67
4	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019, 70, 771-787.	3.6	46
5	Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection. <i>Hepatology</i> , 2015, 61, 812-822.	3.6	37
6	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017, 67, 680-686.	1.8	37
7	Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 114-123.	1.9	37
8	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
9	Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels. <i>International Journal of Molecular Sciences</i> , 2016, 17, 922.	1.8	16
10	Treatment and re-treatment results of HCV patients in the DAA era. <i>PLoS ONE</i> , 2020, 15, e0232773.	1.1	16
11	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	1.3	13
12	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
13	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
14	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
15	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. <i>Viruses</i> , 2021, 13, 1580.	1.5	6
16	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	5
17	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. <i>PLoS ONE</i> , 2016, 11, e0156731.	1.1	5
18	PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure. <i>Journal of Hepatology</i> , 2019, 70, e111.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Not uncommon: HBV genotype G co-infections among healthy European HBV carriers with genotype A and E infection. <i>Liver International</i> , 2021, 41, 1278-1289.	1.9	3
20	Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. <i>Virology</i> , 2015, 485, 213-222.	1.1	2
21	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	1.9	2
22	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101031.	1.6	2
23	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , 2020, 5, .	2.3	2
24	Reply to: "Glecaprevir/pibrentasvir+ sofosbuvir+ ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". <i>Journal of Hepatology</i> , 2021, 75, 254-255.	1.8	1